[1]程洪波,俞菊红,伍柏青,等.减低剂量凝血因子替代治疗在血友病患者微创手术中的疗效[J].医学信息,2020,33(12):110-112.[doi:10.3969/j.issn.1006-1959.2020.12.034]
　CHENG Hong-bo,YU Ju-hong,WU Bo-qin,et al.Efficacy of Reduced-dose Coagulation Factor Replacement Therapy in Minimally Invasive Surgery for Hemophilia Patients[J].Medical Information,2020,33(12):110-112.[doi:10.3969/j.issn.1006-1959.2020.12.034]
点击复制

减低剂量凝血因子替代治疗在血友病患者微创手术中的疗效()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年12期
页码:
110-112
栏目:
临床研究
出版日期:
2020-06-15

文章信息/Info

Title:
Efficacy of Reduced-dose Coagulation Factor Replacement Therapy in Minimally Invasive Surgery for Hemophilia Patients
文章编号:
1006-1959（2020）12-0110-03
作者:
程洪波; 俞菊红; 伍柏青; 等
（江西省人民医院血液科/江西省血友病诊疗中心，江西 南昌 330006）
Author(s):
CHENG Hong-bo; YU Ju-hong; WU Bo-qin; et al
(Department of Hematology,Jiangxi Provincial People’s Hospital/Jiangxi Hemophilia Diagnosis and Treatment Center,Nanchang 330006,Jiangxi,China)
关键词:
血友病; 凝血因子; 替代治疗; 外科手术; 微创手术
Keywords:
Hemophilia; Coagulation factors; Alternative therapy; Surgery; Minimallyinvasive surgery
分类号:
R554+.1
DOI:
10.3969/j.issn.1006-1959.2020.12.034
文献标志码:
A
摘要:
目的 探讨减低剂量凝血因子替代治疗在血友病患者进行微创手术时的疗效。方法 回顾性分析2012年3月~2019年12月我院行血友病微创外科手术的8例患者临床资料，均按照围手术期凝血因子替代治疗方案进行治疗，分析治疗情况、围手术期止血情况分级、术中出血量、术后引流量、凝血因子用时、住院时间、凝血因子用量及并发症发生情况。结果 8例患者行9次微创手术均顺利完成，围手术期止血情况分级判定均为极佳（E级）。术中出血量（20.00±13.45）ml、术中出血量（57.22±34.98）ml、凝血因子用时（5.44±2.19）d、住院时间（13.54±7.48）d、凝血因子用量（260.44±111.63）U/kg。所有手术均未出现急性出血、延迟性出血、血栓、凝血因子抑制物、血制品相关病毒感染、手术部位感染等并发症。结论 减低剂量凝血因子替代治疗在血友病患者微创手术中的疗效满意，在获得良好止血效果的同时，可减少并发症发生风险。
Abstract:
Objective To explore the efficacy of reduced-dose coagulation factor replacement therapy in patients with hemophilia undergoing minimally invasive surgery.Methods The clinical data of 8 patients undergoing minimally invasive surgery for hemophilia in our hospital from March 2012 to December 2019 were retrospectively analyzed. All patients were treated according to the perioperative coagulation factor replacement treatment plan, and the treatment status and perioperative period were analyzed. Grading of hemostasis, intraoperative bleeding volume, postoperative drainage volume, coagulation factor time, hospital stay, coagulation factor dosage, and complications occurred.Results 8 patients underwent 9 minimally invasive operations successfully, and the perioperative hemostasis classification was excellent (grade E), intraoperative blood loss(20.00±13.45) ml, intraoperative blood loss(57.22±34.98) ml,coagulation factor time(5.44±2.19) d, hospital stay (13.54±7.48) d, clotting factor dosage (260.44±111.63) U/kg.No complications such as acute bleeding, delayed bleeding, thrombosis, coagulation factor inhibitors, blood product-related viral infections, or surgical site infections occurred in all operations.Conclusion The reduced-dose coagulation factor replacement therapy is satisfactory in minimally invasive surgery for patients with hemophilia. While obtaining a good hemostatic effect, it can reduce the risk of complications.

参考文献/References:

[1]中华医学会血液学分会血栓与止血学组,中国血友病协作组.血友病诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(5):364-370.[2]Shapiro A,Cooper DL.U.S survey of surgical capabilities and experience with surgical procedures in patients with congenital haemophilia with inhibitors[J].Haemophilia,2012,18(3):400-405.[3]丁秋兰,王学峰,王鸿利,等.血友病诊断和治疗的专家共识［J］.临床血液学杂志,2010,23（3）:121-125.[4]方涛林,马曾辰.血友病患者外科疾病的手术治疗[J].中华外科杂志,2003,41(8):623-626.[5]黄志强.微创外科与外科微创化--21世纪外科的主旋律[J].中华外科杂志,2002,40(1):9-12.[6]Rivastava A,Brewer AK,Mauser-Bunschoten EP,et al.Guidelines for the management of hemophilia[J].Haemophilia,2013,19(1):1-47.[7]Marder VJ,Shulman NR.Major surgery in classic hemophilia using fraction I:experience in twelve operations and review of the literature[J].Am J Med,1966,41(8):56-75.[8]Rains AJ.Annals of the royal college of surgeons of England[J].Annals of the Royal College of Surgeons of England,1974,54(1):1-2.[9]曲艳吉,殷环,庞元捷,等.中国大陆血友病患者治疗现状和经济负担的系统评价[J].中国循证医学杂志,2013,13(2):182-189.[10]肇晖.外科手术微创时代的思考[J].上海医药,2014,35(23):5-6.[11]Tong KM,Wang JD,Chang ST,et al.Outcome of perioperative hemostatic management in patients with hemophilia without inhibitors undergoing 161 invasive or surgical procedures[J].J Chin Med Assoc,2018,81(10):926-929.[12]中华医学会血液学分会血栓与止血学组,中国血友病协作组.凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版)[J].中华血液学杂志,2018,39(10):793-799.[13]胡健,彭捷,阳红斌,等.血友病A患者围手术期凝血因子Ⅷ替代治疗的疗效评价[J].中国药师,2018,21(7):1199-1201.[14]Goldmann G,Holoborodska Y,Oldenburg J,et al.Perioperative management and outcome of general and abdominal surgery in hemophiliacs[J].Am J Surg,2010,199(5):702-707.

更新日期/Last Update: 1900-01-01